<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250629066290N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-07-16</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>The effect of emotion-focused therapy on anxiety, stress, and repetitive thoughts in diabetic women in Ahvaz</public_title>
      <acronym>EFSRD</acronym>
      <scientific_title>Studying the effectiveness of emotion-focused therapy on anxiety sensitivity, perceived stress, action flexibility, and rumination in women undergoing medical treatment with type 2 diabetes in Ahvaz city.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-07-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/84537</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: 1.Randomization Method &amp; Description:
- Method Used:Simple Random Allocation
  - Participants were randomly assigned (via lottery draw) to either the intervention or control group.  
  - No manipulation or bias in group selection was applied.  

2. Unit of Randomization:
- Individual:Each participant was randomized independently.  
3. Stratification (if applicable):  
- Not Used:  
  - Due to the relatively small sample size (N=40) and homogeneity of the study population (all women with type 2 diabetes), stratification was not applied.  
4. Randomization Tool:
- Manual (Lottery Draw):
  - Names were written on separate papers, mixed in a container, and drawn randomly.  
  - Digital tools (e.g., randomization software) were not used due to practical constraints.  
5. Sequence Generation:
- Unpredictable Sequence:
  - The order of drawing names from the container determined the random sequence.  

6. Allocation Concealment:
- Partial Concealment: 
  - Researchers and participants were aware of group allocation post-randomization.  
  - However, outcome assessments (pre-test/post-test) were conducted by blinded assessors to minimize measurement bias.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Type 2 Diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: - Description:This group consisted of 20 women with type 2 diabetes who received Emotion-Focused Therapy (EFT).- Key Characteristics: - Intervention Method:- 8 weekly sessions (90 minutes each)- Protocol based on Greenberg's (2004) model and the manual by Rasouli &amp; Pour Ebrahim (2010) - Focused on emotion regulation, emotional processing, and reduction of rumination- Concurrent Conditions:- Continued standard pharmacological treatment (no dosage changes during the study)- No concurrent participation in other psychotherapy. Intervention 2: Control group: Description:This group consisted of 20 women with type 2 diabetes who received only standard pharmacological treatment and no psychotherapy intervention.- Key Features:- Follow-up method: - Received routine medical care (same as the intervention group)- Did not receive Emotion-Focused Therapy (EFT) or any structured psychotherapy during the study- Controlled conditions:- Assessed at the same time intervals (pre-test, post-test, follow-up)- Were unaware of the intervention group’s session content (partial blinding).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zainab Ahangarpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.107, West 20th Alley, Kianabad, Ahvaz</address>
        <city>ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6155754816</zip>
        <telephone>+98 61 3337 8937</telephone>
        <email>zeinabahangarpour@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sasan Bavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz, Farhang Shahr, Ahvaz Azad University</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۶۱۳۴۹۳۷۳۳۳</zip>
        <telephone>+98 916 607 5133</telephone>
        <email>Sasanbavi2@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women aged 20 to 40 years with type 2 diabetes
No history of substance use and no current or previous major psychiatric symptoms; no history of brain diseases such as brain tumors
Not participating in other psychotherapy sessions for at least one month before the study
Signing a written informed consent form and commitment to participate in treatment sessions
Minimum education level: diploma (high school degree)
Definite diagnosis of type 2 diabetes by a specialist physician</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Having brain diseases such as brain tumors
Presence of current or past psychotic symptoms or severe psychiatric disorders
Substance abuse
Participation in other psychotherapy sessions at least one month before the study
Not having at least a high school diploma
No confirmed diagnosis of type 2 diabetes by a specialist physician
Unwillingness to participate or refusal to sign the written informed consent form</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E08</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes mellitus due to underlying condition</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: - Description:This group consisted of 20 women with type 2 diabetes who received Emotion-Focused Therapy (EFT).- Key Characteristics: - Intervention Method:- 8 weekly sessions (90 minutes each)- Protocol based on Greenberg's (2004) model and the manual by Rasouli &amp; Pour Ebrahim (2010) - Focused on emotion regulation, emotional processing, and reduction of rumination- Concurrent Conditions:- Continued standard pharmacological treatment (no dosage changes during the study)- No concurrent participation in other psychotherapy</i_keyword>
      <i_keyword>Control group: Description:This group consisted of 20 women with type 2 diabetes who received only standard pharmacological treatment and no psychotherapy intervention.- Key Features:- Follow-up method: - Received routine medical care (same as the intervention group)- Did not receive Emotion-Focused Therapy (EFT) or any structured psychotherapy during the study- Controlled conditions:- Assessed at the same time intervals (pre-test, post-test, follow-up)- Were unaware of the intervention group’s session content (partial blinding)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>1. Anxiety Sensitivity - Measurement: Total score of the Anxiety Sensitivity Index-3 (ASI-3) - Change indicator:Reduction of ≥30% from baseline.       Primary Outcomes:Change in Anxiety Sensitivity (ASI-3) score at the end of the intervention. Timepoint: 1. Pre-test:Measurement of dependent variable (anxiety sensitivity) before the intervention began for both experimental and control groups.                     2. Post-test:Re-measurement of variable immediately after completing the treatment sessions (after 8 sessions of Emotion-Focused Therapy).              3.Follow-up:Measurement of variable one month after the intervention ended to assess the durability of treatment effects. Method of measurement: 1. Anxiety Sensitivity  - Tool: Anxiety Sensitivity Index (ASI) - Original version:* Reiss et al. (1985) - Persian version:Used in domestic studies with confirmed validity and reliability  - Description: - Consists of 16 items assessing fear of anxiety symptoms (e.g., "When my heart beats rapidly, I get scared"). -Three subscales: Physical, cognitive, and social concerns.- Scoring: 5-point Likert scale (0=Not at all to 4=Very much).</prim_outcome>
      <prim_outcome>2. Perceived Stress - Measurement: Total score of the Perceived Stress Scale-10 (PSS-10) -Change indicator: Reduction of ≥25% from baseline.  Primary Outcomes:Change in Perceived Stress (PSS-10) score at the end of the intervention. Timepoint: 1. Pre-test:Measurement of dependent variable ( perceived stress) before the intervention began for both experimental and control groups.                     2. Post-test:Re-measurement of variable immediately after completing the treatment sessions (after 8 sessions of Emotion-Focused Therapy).              3.Follow-up:Measurement of variable one month after the intervention ended to assess the durability of treatment effects. Method of measurement: 2. Perceived Stress  - Tool: Perceived Stress Scale (PSS) - Original version:* Cohen et al. (1983)- Persian version:Safaei &amp; Shokri (2014) with satisfactory validity and reliability- Description: - 14 items evaluating an individual’s perception of stressful situations (e.g., "How often have you felt nervous or stressed in the past month?").- 5-point Likert scale (0=Never to 4=Very often).</prim_outcome>
      <prim_outcome>3. Psychological Flexibility - Measurement: Total score of the Connor-Davidson Resilience Scale-10 (CD-RISC-10) - Change indicator: Increase of ≥20% from baseline.  Primary Outcomes: Change in Psychological Flexibility (CD-RISC-10) score at 1-month follow-up. Timepoint: 1. Pre-test:Measurement of dependent variable (cognitive flexibility) before the intervention began for both experimental and control groups.                     2. Post-test:Re-measurement of variable immediately after completing the treatment sessions (after 8 sessions of Emotion-Focused Therapy).              3.Follow-up:Measurement of variable one month after the intervention ended to assess the durability of treatment effects. Method of measurement: 3. Cognitive Flexibility  -Tool: Cognitive Flexibility Inventory (CFI) - Original version:Dennis &amp; Vander Wal (2010)- Persian version:Ghorbani &amp; Kaviani (2015)- Description:- 20 items measuring the ability to adapt thinking to new conditions (e.g., "I can think of multiple solutions to a problem"). 7-point Likert scale (1=Strongly disagree to 7=Strongly agree).</prim_outcome>
      <prim_outcome>4.Rumination -Measurement: Total score of the Ruminative Response Scale (RRS) - Change indicator: Reduction of ≥15% from baseline.Primary Outcomes: Change in Rumination (RRS) score at the end of the intervention. Timepoint: 1. Pre-test:Measurement of dependent variable (Rumination) before the intervention began for both experimental and control groups.                     2. Post-test:Re-measurement of variable immediately after completing the treatment sessions (after 8 sessions of Emotion-Focused Therapy).              3.Follow-up:Measurement of variable one month after the intervention ended to assess the durability of treatment effects. Method of measurement: 4. Rumination  - Tool: Ruminative Responses Scale (RRS) - Original version: Nolen-Hoeksema &amp; Morrow (1991) - Persian version:Bagherinejad et al.(2011)- Description:- 22 items assessing repetitive negative thoughts (e.g., "I think about how sad I feel").-4-point Likert scale (1=Almost never to 4=Almost always). --- Procedure1. Pre-test: All participants completed the questionnaires before the intervention. 2. Post-test: Both groups were reassessed after 8 sessions of Emotion-Focused Therapy (EFT).3. Follow-up: The experimental group was reevaluated one month later to assess the persistence of effects.Data Analysis  - A Mixed ANOVA (Repeated Measures ANOVA) was used to compare changes across three time points (pre-test, post-test, follow-up) between the two groups.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-04-05</approval_date>
        <contact_name>Ethics Committee of Islamic Azad University of Ahvaz</contact_name>
        <contact_address>Ahvaz Golestan-Farhangshahr Highway ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
